Evidence map›Paper›PMID 39678546›Full record

ArticleAmerican journal of translational research2024

Effect of body mass index on breast cancer prognosis: a focus on ER/PR status and subtype-specific recurrence risk.

Qinyan Shen, Liangying Zhao, Minjun Lu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in American journal of translational research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Qinyan ShenDepartment of Surgical Oncology, Affiliated Dongyang Hospital of Wenzhou Medical University Dongyang 322100, Zhejiang, China.
Liangying ZhaoDepartment of Surgical Oncology, Affiliated Dongyang Hospital of Wenzhou Medical University Dongyang 322100, Zhejiang, China.
Minjun LuDepartment of Surgical Oncology, Affiliated Dongyang Hospital of Wenzhou Medical University Dongyang 322100, Zhejiang, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo explore prognostic differences in breast cancer (BC) recurrence risk across estrogen receptor (ER) and progesterone receptor (PR) defined subtypes, stratified by body mass index (BMI) categories, aiming to identify potential mechanisms.

methodsA cohort of 358 breast cancer patients provided data on height, weight, menopausal status, and receptor profiles for analysis.

resultsOur findings highlighted that BMI's impact on BC prognosis was significantly influenced by ER/PR tumor status. In premenopausal women, BMI notably affected recurrence rates, especially in patients with ER-positive and PR-positive subtypes.

conclusionsAdjusting treatment strategies based on BMI across different menopausal statuses and tumor subtypes could improve outcome for patients with ER-positive/PR-positive tumors.

Indexed as

body mass indexbreast cancer recurrenceestrogen receptorHeightprogesterone receptor

Identifiers

PMID39678546
PMCPMC11645606

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.